Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL73830 | 1.00 | LMNA (0.38) | LMNAPDE7AADAM17ADAMTS5KDM4E | |
| SCHEMBL2976203 | 0.82 | ADAMTS5 (0.37) | LMNAPDE7AADAM17ADAMTS5ALDH1A1 | |
| SCHEMBL1404437 | 0.80 | LMNA (0.50) | LMNAPDE7AADAM17ADAMTS5KDM4E | |
| SCHEMBL6662375 | 0.76 | LMNA (0.43) | LMNAPDE7AADAM17ADAMTS5KDM4E | |
| SCHEMBL75900 | 0.73 | MMP13 (0.41) | ADAMTS5ALDH1A1 | |
| SCHEMBL27758977 | 0.73 | LMNA (0.40) | LMNAPDE7AADAM17ADAMTS5KDM4E | |
| SCHEMBL74108 | 0.73 | MMP13 (0.41) | ADAMTS5ALDH1A1 | |
| SCHEMBL2967822 | 0.73 | MMP13 (0.41) | ADAMTS5ALDH1A1 | |
| SCHEMBL940749 | 0.73 | PLA2G7 (0.33) | — | |
| SCHEMBL24928304 | 0.72 | LMNA (0.43) | LMNAPDE7AADAM17ADAMTS5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256166-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2010-10-07 | — | — | US | disclosed |
| US-7772403-B2 | Process to prepare sulfonyl chloride derivatives | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-20090105305-A1 | Therapeutic Agents - 550 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| CN-101405273-A | Process to prepare sulfonyl chloride derivatives | ASTRAZENECA AB (SE) | 2009-04-08 | — | — | CN | disclosed |
| US-20090054659-A1 | Process to Prepare Sulfonyl Chloride Derivatives | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1999115-A1 | PROCESS TO PREPARE SULFONYL CHLORIDE DERIVATIVES | AstraZeneca AB (SE) | 2008-12-10 | — | — | EP | disclosed |
| WO-2008075070-A1 | SULFONAMIDE DERIVATIVES FOR THERAPEUTIC USE AS FATTY ACID SYNTHASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2007106021-A1 | PROCESS TO PREPARE SULFONYL CHLORIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | disclosed |
| US-20060019994-A1 | I-sulphonlyl piperidine derivatives | ASTRAZENECA AB (SE) | 2006-01-26 | — | — | US | disclosed |
| US-20050256176-A1 | Sulphonamide derivatives and their use as tace inhibitors | ASTAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1539740-A1 | SULPHONAMIDE DERIVATIVES AND THEIR USE AS TACE INHIBITORS | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| EP-1539706-A1 | 1-SULPHONYL PIPERIDINE DERIVATIVES | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024715-A1 | SULPHONAMIDE DERIVATIVES AND THEIR USE AS TACE INHIBITORS | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004024698-A1 | 1-SULPHONYL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256176-A1 | Sulphonamide derivatives and their use as tace inhibitors | ADAM10, ADAM17, TNF | LMNA 2017/4885PDE7A 2902/4885ADAM17 2/4885 |
| US-20090105305-A1 | Therapeutic Agents - 550 | FABP4, GPR119, FASN | LMNA 2831/4885PDE7A 1679/4885ADAM17 2509/4885 |
| US-20060019994-A1 | I-sulphonlyl piperidine derivatives | MMP1, TPSAB1, CASP1 | LMNA 4174/4885PDE7A 3403/4885ADAM17 105/4885 |
| US-20100256166-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | MMP1, MMP2, MMP9 | LMNA 1175/4885PDE7A 829/4885ADAM17 19/4885 |
| US-20090054659-A1 | Process to Prepare Sulfonyl Chloride Derivatives | SLC5A1, GCG, IAPP | LMNA 1199/4885PDE7A 1900/4885ADAM17 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.